Dosing and Administration

Premedication with antiemetics should be administered prior to the start of the amino acid solution infusion.¹

Initiate an IV infusion of a sterile amino acid solution containing L-lysine and L-arginine 30 minutes before the start of the LUTATHERA infusion.¹

• Use a 3-way valve to administer the amino acid solution using the same venous access as LUTATHERA or administer the amino acid solution through a separate venous access in the patient’s other arm¹
• Continue the infusion during and for at least 3 hours after completion of the infusion of LUTATHERA¹  
• Do not decrease the dose of the amino acid solution if a reduced dose of LUTATHERA is administered¹
• For more information about the amino acid solution, please refer to the full Prescribing Information for LUTATHERA

^aEquivalent to 14.4 g to 20 g L-lysine.^1 
bEquivalent to 14.9 g to 20.7 g L-arginine.¹

• 7.4 GBq (200 mCi) of LUTATHERA is administered IV over 30 to 40 minutes using the gravity method¹
• Do not inject LUTATHERA directly into any other IV solution¹

The gravity method, peristaltic pump method, or the syringe pump method may be used for the administration of the recommended dosage. Use the peristaltic pump or syringe pump method when administering a reduced dose of LUTATHERA following a dosage modification for an adverse reaction. When using the gravity method for a reduced dose, adjust the LUTATHERA dose before the administration to avoid the delivery of an incorrect volume of LUTATHERA.¹

• For instructions on how to use the gravity method, peristaltic pump method, or the syringe pump method to administer LUTATHERA, please refer to the full Prescribing Information^1,2

• Patients will have periodic liver function tests and blood work 
  – General LUTATHERA recommendations include tests 2 to 4 weeks before each treatment cycle 
• Monitor for signs and symptoms of tumor-related hormonal release

• Premedication is required for patients with a history of grade 1/2 hypersensitivity reactions to LUTATHERA before subsequent doses  
• Please refer to the Prescribing Information for LUTATHERA for important details on patient hypersensitivity monitoring and discontinuation

• Patients should hydrate before, the day of, and the day after administration of LUTATHERA

• Patients will be monitored for signs and symptoms of hypersensitivity reactions, including anaphylaxis, during and following LUTATHERA administration for a minimum of 2 hours in a setting where cardiopulmonary resuscitation medication and equipment are available

• The treating nuclear medicine institution will provide patients with detailed instructions regarding their treatment procedures, including preparation, discharge precautions, and ways to avoid or minimize radiation exposure to household contacts
• Patient education materials can be downloaded from the Resources section